Opinion
Video
Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.
EP: 1.Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer
Now Viewing
EP: 2.Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer
EP: 3.Evolving Treatment Paradigm and NCCN Guideline Updates
EP: 4.The EMBARK trial investigating enzalutamide in NM CSPC
EP: 5.The Role of PSA Doubling Time in Risk Assessment
EP: 6.Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA
EP: 7.Patient Case 2: Metastatic CSPC
EP: 8.Final Thoughts on CSPC
- Dr. Efstathiou asks Dr. Freedland: What are the key factors you consider in risk stratification of your patients? What clinical characteristics and existing biomarkers help guide your assessment?
- What promising biomarkers have emerged that may help detect early signs of prostate cancer progression? (Logan Cancers 2023, Kumaraswamy JCI Insight 2023, please highlight any others)
Related Videos
Related Content
